Last reviewed · How we verify
CELSIOR® group
CELSEOR is a glucagon receptor agonist.
CELSEOR is a glucagon receptor agonist. Used for Hypoglycemia for prevention in patients with type 1 diabetes.
At a glance
| Generic name | CELSIOR® group |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Drug class | Glucagon receptor agonist |
| Target | Glucagon receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
It works by activating the glucagon receptor, which increases glucose levels in the bloodstream, and is being investigated for the treatment of hypoglycemia in patients with type 1 diabetes.
Approved indications
- Hypoglycemia for prevention in patients with type 1 diabetes
Common side effects
- Nausea
- Vomiting
- Abdominal pain
Key clinical trials
- HOPE Against Cancer Recurrence in HCC (PHASE4)
- A Retrospective Comparison of the Efficacy and Safety of Celsior® in Pediatric Cardiac Surgery for Transposition of the Great Vessels
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CELSIOR® group CI brief — competitive landscape report
- CELSIOR® group updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI